TAUNS Laboratories,Inc.

197A TSE Pharmaceuticals Pharmaceutical
TSE Standard
¥502.00
-0.20%
Delayed · cached 15 min

Fair value analysis

197A
TAUNS Laboratories,Inc.
PharmaceuticalsPharmaceutical
¥502.00
Close used for this calculation
¥723.97Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
73/100
Profitability12/25
Returns23/25
Balance Sheet13/25
Efficiency25/25
Growth13/25
Strong
Quality radar
73Prof.12/25Ret.23/25Eff.25/25B.Sht13/25Growth13/25

Consensus fair value

¥723.97
Below FV
▲ +44.2% against the close used
Model range ¥357.15 – ¥1,241.40
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear¥357.15Fair value¥723.97Bull¥1,241.40
FairClose
52-week traded range
52W low ¥464.0052W high ¥574.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

TAUNS Laboratories,Inc. closed at ¥502.00, 30.7% below the consensus fair value of ¥723.97 drawn from 8 valuation models.

Financial DNA score 73/100 — Strong. P/E of 8.1x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
¥393.93
-21.5%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
¥485.85
-3.2%
√(22.5 × EPS × BVPS)
EPS=62.07, BVPS=169.02 · outside Graham range (P/E 8.1, P/B 3) — asset-light, treat as a rough floor
P/E Fair Value
¥1,241.40
+147.3%
EPS × 20x (sector P/E)
EPS=62.07, Sector P/E=20x
EV/EBITDA
¥751.82
+49.8%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=8.98B
Dividend Discount (DDM)
¥357.15
-28.9%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=28.01, r=10%, g=2%
Book Value (P/B)
¥910.31
+81.3%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=169.02, ROE=40.7%, g=3%, r=10%
Reverse DCF
¥502.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -5.3% | Historical: 0%
Margin of Safety
¥530.30
+5.6%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=707.06, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.